Sirolimus
- Generic Name
- Sirolimus
- Brand Names
- Fyarro, Hyftor, Rapamune
- Drug Type
- Small Molecule
- Chemical Formula
- C51H79NO13
- CAS Number
- 53123-88-9
- Unique Ingredient Identifier
- W36ZG6FT64
- Background
Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria Streptomyces hygroscopicus, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after its potent antitumor and immunosuppressive a...
- Indication
Sirolimus is indicated for the prophylaxis of organ rejection in patients aged 13 years or older receiving renal transplants. In patients at low-to moderate-immunologic risk, it is recommended that sirolimus be used initially in a regimen with cyclosporine and corticosteroids; cyclosporine should be withdrawn two to four months after transplantation. In pati...
- Associated Conditions
- Chordomas, Facial Angiofibroma, Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Liver Transplant Rejection, Lung Transplant Rejection, Lymphangioleiomyomatosis (LAM), Renal Angiomyolipomas, Transplanted Organ Rejection, Metastatic malignant Perivascular Epithelioid Cell Neoplasms, Unresectable, locally advanced malignant Perivascular Epithelioid Cell Neoplasms
- Associated Therapies
- -
Combination Drug Therapy Followed by Single Drug Steroid Free Therapy to Prevent Organ Rejection in Kidney Transplantation
- First Posted Date
- 2004-01-27
- Last Posted Date
- 2013-10-16
- Target Recruit Count
- 31
- Registration Number
- NCT00076570
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Sirolimus in Treating Young Patients With Relapsed or Refractory Acute Leukemia or Non-Hodgkin's Lymphoma
- First Posted Date
- 2003-09-11
- Last Posted Date
- 2015-03-12
- Lead Sponsor
- Children's Hospital of Philadelphia
- Target Recruit Count
- 10
- Registration Number
- NCT00068302
- Locations
- 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Improving the Results of Bone Marrow Transplantation for Patients With Severe Congenital Anemias
- First Posted Date
- 2003-05-29
- Last Posted Date
- 2024-02-29
- Target Recruit Count
- 130
- Registration Number
- NCT00061568
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Sirolimus in Treating Patients With Glioblastoma Multiforme
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-08-03
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 13
- Registration Number
- NCT00047073
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
Sirolimus Therapy for Idiopathic and Lupus Membranous Nephropathy
- Conditions
- First Posted Date
- 2002-12-18
- Last Posted Date
- 2017-10-06
- Target Recruit Count
- 12
- Registration Number
- NCT00050713
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas
- Conditions
- Interventions
- Drug: F-18 FluorodeoxyglucoseBiological: therapeutic allogeneic lymphocytesProcedure: Peripheral Blood Stem Cell donationDrug: cyclophosphamideDrug: cyclosporineDrug: doxorubicin hydrochlorideDrug: etoposideDrug: fludarabine phosphateDrug: melphalanDrug: prednisoneDrug: sirolimusDrug: tacrolimusDrug: vincristine sulfateProcedure: peripheral blood stem cell transplantationDrug: Filgrastim
- First Posted Date
- 2002-08-16
- Last Posted Date
- 2017-05-31
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 60
- Registration Number
- NCT00043979
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Sirolimus for Focal Segmental Glomerulosclerosis
- Conditions
- First Posted Date
- 2002-06-27
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 30
- Registration Number
- NCT00040508
- Locations
- 🇺🇸
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Bethesda, Maryland, United States
Study Comparing Conversion to Sirolimus vs. Continued Use of Calcineurin Inhibitors in Kidney Transplant Recipients
- Conditions
- Interventions
- First Posted Date
- 2002-06-07
- Last Posted Date
- 2010-05-14
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 830
- Registration Number
- NCT00038948
Steroid Withdrawal in Pediatric Kidney Transplant Recipients
- Conditions
- Interventions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2016-10-21
- Target Recruit Count
- 274
- Registration Number
- NCT00023244
- Locations
- 🇺🇸
University of Florida Health Science Center, Jacksonville, Florida, United States
🇺🇸The Children's Hospital of Buffalo, Buffalo, New York, United States
🇺🇸Westchester Medical Center, Valhalla, New York, United States
A Study to Compare Treatment With Sirolimus Versus Standard Treatment in Patients Who Have Received a Kidney Transplant
- Conditions
- Interventions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2012-03-13
- Lead Sponsor
- Boston Children's Hospital
- Target Recruit Count
- 102
- Registration Number
- NCT00005113
- Locations
- 🇺🇸
Children's Hospital Boston, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.